Last Name


Kalipada Pahan to Neuronal Ceroid-Lipofuscinoses

This is a "connection" page, showing publications Kalipada Pahan has written about Neuronal Ceroid-Lipofuscinoses.

Connection Strength
  1. Kim K, Kleinman HK, Lee HJ, Pahan K. Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders. Orphanet J Rare Dis. 2017 06 17; 12(1):113.
    View in: PubMed
    Score: 0.662
  2. Ghosh A, Rangasamy SB, Modi KK, Pahan K. Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis. J Neurochem. 2017 05; 141(3):423-435.
    View in: PubMed
    Score: 0.652
  3. Ghosh A, Corbett GT, Gonzalez FJ, Pahan K. Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor a: implications for late infantile Batten disease therapy. J Biol Chem. 2012 Nov 09; 287(46):38922-35.
    View in: PubMed
    Score: 0.476
  4. Chakrabarti S, Chandra S, Roy A, Dasarathi S, Kundu M, Pahan K. Upregulation of tripeptidyl-peptidase 1 by 3-hydroxy-(2,2)-dimethyl butyrate, a brain endogenous ligand of PPARa: Implications for late-infantile Batten disease therapy. Neurobiol Dis. 2019 07; 127:362-373.
    View in: PubMed
    Score: 0.187
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.